OncoMatch/Clinical Trials/NCT07230509

Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate

Is NCT07230509 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Pancreatic parenchymal for pancreaticoduodenectomy.

Phase 2RecruitingMinia UniversityNCT07230509Data as of May 2026

Treatment: Pancreatic parenchymal — This randomized controlled trial investigates the safety and efficacy of injecting N-butyl-2- cyanoacrylate (Histoacryl®) into the pancreatic parenchyma during pancreaticoduodenectomy (PD) to enhance the security of the pancreaticojejunostomy (PJ) anastomosis and reduce postoperative pancreatic fistula (POPF) rates.

Check if I qualify

Extracted eligibility criteria

Cancer type

Pancreatic Cancer

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify